Evaluation of Ghrelin, Nesfatin-1 and Irisin Levels of Serum and Brain After Acute or Chronic Pentylenetetrazole Administrations in Rats Using Sodium Valproate

dc.contributor.author Erkec, Ozlem Ergul
dc.contributor.author Algul, Sermin
dc.contributor.author Kara, Mehmet
dc.date.accessioned 2025-05-10T17:44:04Z
dc.date.available 2025-05-10T17:44:04Z
dc.date.issued 2018
dc.description Kara, Mehmet/0000-0002-8864-9706 en_US
dc.description.abstract Objectives: In this study, we aim to reveal the alterations (due to seizure) in the serum and brain levels of nesfatin-1, ghrelin and irisin after acute or chronic pentylenetetrazole administrations in rats using sodium valproate. Methods: 35 Wistar albino rats were randomly divided into five groups: Control, Acute Pentylenetetrazole group (APTZ), Acute Pentylenetetrazole+ Valproate group (AVPA), PTZ kindling group (PTZk) and PTZ kindling+ Valproate group (KVPA). Serum and brain levels of ghrelin, nesfatin-1 and FNDC5/irisin were determined with ELISA. Results: Serum levels of ghrelin were significantly decreased in APTZ and PTZk groups compared to the control (p < 0.01). There was a statistically significant decrease in brain levels of ghrelin in all groups compared to the control group (p < 0.01). There was a statistically significant increase in serum nesfatin-1 levels in the APTZ and PTZk groups compared to the control (p < 0.05). Serum levels of nesfatin-1 were similar to the control group in both the acute and the chronic treatment groups. There was a statistically significant increase in brain nesfatin-1 levels of the KVPA group compared to the control (p < 0.05). Serum and brain levels of FNDC5/irisin were found significantly increased in APTZ, AVPA and PTZk groups compared to the control (p < 0.01). Conclusions: Statistically significant alterations were detected in the serum and brain levels of these three peptides in both the PTZ-induced chronic epilepsy model and acute seizure model. The results of this study may suggest that the increase in FNDC5/irisin and nesfatin-1 levels, and the decrease in ghrelin levels may contribute to seizure pathophysiology. However, further studies are needed in order to confirm our hypothesis. en_US
dc.description.sponsorship Research Fund of the Van Yuzuncu Yil University [TSA-2017-5894] en_US
dc.description.sponsorship This work was supported by the Research Fund of the Van Yuzuncu Yil University [grant number TSA-2017-5894]. en_US
dc.identifier.doi 10.1080/01616412.2018.1503992
dc.identifier.issn 0161-6412
dc.identifier.issn 1743-1328
dc.identifier.scopus 2-s2.0-85052109547
dc.identifier.uri https://doi.org/10.1080/01616412.2018.1503992
dc.identifier.uri https://hdl.handle.net/20.500.14720/16069
dc.language.iso en en_US
dc.publisher Taylor & Francis Ltd en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Brain en_US
dc.subject Epilepsy en_US
dc.subject Ghrelin en_US
dc.subject Fndc5/Irisin en_US
dc.subject Kindling en_US
dc.subject Nesfatin-1 en_US
dc.subject Pentylenetetrazole en_US
dc.subject Seizure en_US
dc.title Evaluation of Ghrelin, Nesfatin-1 and Irisin Levels of Serum and Brain After Acute or Chronic Pentylenetetrazole Administrations in Rats Using Sodium Valproate en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.id Kara, Mehmet/0000-0002-8864-9706
gdc.author.scopusid 57193334079
gdc.author.scopusid 56318101800
gdc.author.scopusid 7006159432
gdc.author.wosid Erkec, Ozlem/A-2042-2017
gdc.author.wosid Kara, Mehmet/F-4040-2011
gdc.coar.access metadata only access
gdc.coar.type text::journal::journal article
gdc.description.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
gdc.description.departmenttemp [Erkec, Ozlem Ergul; Algul, Sermin; Kara, Mehmet] Van Yuzuncu Yil Univ, Dept Physiol, Fac Med, Van, Turkey en_US
gdc.description.endpage 929 en_US
gdc.description.issue 11 en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q3
gdc.description.startpage 923 en_US
gdc.description.volume 40 en_US
gdc.description.woscitationindex Science Citation Index Expanded
gdc.description.wosquality Q4
gdc.identifier.pmid 30111257
gdc.identifier.wos WOS:000447140600003
gdc.index.type WoS
gdc.index.type Scopus
gdc.index.type PubMed

Files